KR20050108383A - 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도 - Google Patents

이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도 Download PDF

Info

Publication number
KR20050108383A
KR20050108383A KR1020057016936A KR20057016936A KR20050108383A KR 20050108383 A KR20050108383 A KR 20050108383A KR 1020057016936 A KR1020057016936 A KR 1020057016936A KR 20057016936 A KR20057016936 A KR 20057016936A KR 20050108383 A KR20050108383 A KR 20050108383A
Authority
KR
South Korea
Prior art keywords
substituted
phenyl
alkyl
hydroxy
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057016936A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 브라이언트 바트
귀도 볼드
선규 김
티모시 마이클 램지
마이클 로이드 사비오
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20050108383A publication Critical patent/KR20050108383A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
KR1020057016936A 2003-03-11 2004-03-10 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도 Ceased KR20050108383A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11
US60/453,624 2003-03-11

Publications (1)

Publication Number Publication Date
KR20050108383A true KR20050108383A (ko) 2005-11-16

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057016936A Ceased KR20050108383A (ko) 2003-03-11 2004-03-10 이소퀴놀린 유도체의 암 및 map 키나제 관련 질병의치료를 위한 용도

Country Status (22)

Country Link
EP (1) EP1603566B1 (enExample)
JP (1) JP2006519807A (enExample)
KR (1) KR20050108383A (enExample)
CN (1) CN1758910A (enExample)
AT (1) ATE421324T1 (enExample)
AU (1) AU2004218914A1 (enExample)
BR (1) BRPI0408257A (enExample)
CA (1) CA2518530A1 (enExample)
DE (1) DE602004019193D1 (enExample)
ES (1) ES2318276T3 (enExample)
HR (1) HRP20050788A2 (enExample)
IS (1) IS8064A (enExample)
MA (1) MA27724A1 (enExample)
MX (1) MXPA05009687A (enExample)
NO (1) NO20054647L (enExample)
PL (1) PL1603566T3 (enExample)
PT (1) PT1603566E (enExample)
RU (1) RU2325159C2 (enExample)
TN (1) TNSN05223A1 (enExample)
TW (1) TW200501955A (enExample)
WO (1) WO2004080464A1 (enExample)
ZA (1) ZA200506571B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336678B1 (ko) * 2005-07-26 2013-12-04 사노피 Rho-키나제 억제제로서의 사이클로헥실아민 이소퀴놀론유도체
KR20190133378A (ko) 2018-05-23 2019-12-03 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2006089781A1 (en) * 2005-02-25 2006-08-31 Novartis Ag Pharmaceutical combination of bcr-abl and raf inhibitors
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag B−Rafキナーゼ阻害剤に対する感受性についての診断試験
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ES2342240T3 (es) * 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
US20030078271A1 (en) * 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ATE497603T1 (de) * 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
CA2471314A1 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336678B1 (ko) * 2005-07-26 2013-12-04 사노피 Rho-키나제 억제제로서의 사이클로헥실아민 이소퀴놀론유도체
KR20190133378A (ko) 2018-05-23 2019-12-03 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치

Also Published As

Publication number Publication date
AU2004218914A1 (en) 2004-09-23
TNSN05223A1 (en) 2007-06-11
RU2005131168A (ru) 2006-05-27
HRP20050788A2 (en) 2006-12-31
JP2006519807A (ja) 2006-08-31
ES2318276T3 (es) 2009-05-01
TW200501955A (en) 2005-01-16
EP1603566A1 (en) 2005-12-14
BRPI0408257A (pt) 2006-03-07
WO2004080464A1 (en) 2004-09-23
IS8064A (is) 2005-10-10
CA2518530A1 (en) 2004-09-23
EP1603566B1 (en) 2009-01-21
NO20054647D0 (no) 2005-10-10
ZA200506571B (en) 2006-07-26
MXPA05009687A (es) 2005-10-20
RU2325159C2 (ru) 2008-05-27
DE602004019193D1 (de) 2009-03-12
CN1758910A (zh) 2006-04-12
ATE421324T1 (de) 2009-02-15
NO20054647L (no) 2005-12-09
MA27724A1 (fr) 2006-01-02
PL1603566T3 (pl) 2009-07-31
PT1603566E (pt) 2009-04-27

Similar Documents

Publication Publication Date Title
EP4081524B1 (en) Substituted heteroaryl compounds useful as t cell activators
ES2536313T3 (es) Imidazo[4,5-c]quinolinas como inhibidores de ADN–-PK
KR20070009530A (ko) 증식성 질환 치료에 유용한 raf-키나아제 억제제로서의1,4-이치환된 이소퀴놀린 유도체
US11396495B2 (en) Amine compound for inhibiting SSAO/VAP-1 and use thereof
US6608071B2 (en) Isoquinoline derivatives with angiogenesis inhibiting activity
JP4673977B2 (ja) 炎症性疾患治療用フタラジン誘導体
JP2023513675A (ja) Kras変異に関連する癌の予防または治療のための医薬組成物
RU2707730C2 (ru) Пиридиновые соединения пладиенолида и способы применения
US20030130280A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
EP1603566B1 (en) Use of isoquinoline derivatives for treating cancer and map kinase related diseases
AU2002360314A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
US20170174713A1 (en) Tank-binding kinase inhibitor compounds
TW201706267A (zh) 硝基苄基衍生物抗癌試劑
AU2018309739B2 (en) Compounds, Compositions, and Methods for Treating T-cell Acute Lymphoblastic Leukemia
US9861679B2 (en) Method of treating cancer
US20230202992A1 (en) Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same
AU2008200070A1 (en) Use of isoquinoline derivatives for treating cancer and MAP kinase related diseases
KR20200030466A (ko) 7-하이드록시-4H-티에노[3,2-b]피리딘-5-온 유도체 및 그의 용도
WO2024260410A1 (zh) Otub2抑制剂及其在肿瘤免疫中的应用
WO2025085652A1 (en) Indole carboxamides useful as rac1 inhibitors
WO2025034569A9 (en) Sting inhibitors and methods of using thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050909

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090310

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110103

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20111004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110103

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I